CA Patent

CA3167093A1 — Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Assigned to Ariad Pharmaceuticals Inc · Expires 2014-06-12 · 12y expired

What this patent protects

Crystalline Form C of 3-(imidazo[1,2-b]pyridazin-3-ylethyny1)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of preparation and use are disclosed herein.

USPTO Abstract

Crystalline Form C of 3-(imidazo[1,2-b]pyridazin-3-ylethyny1)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of preparation and use are disclosed herein.

Drugs covered by this patent

Patent Metadata

Patent number
CA3167093A1
Jurisdiction
CA
Classification
—
Expires
2014-06-12
Drug substance claim
No
Drug product claim
No
Assignee
Ariad Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.